newsfilter
← Latest News
GlobeNewswire·

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable